PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

Introduction: There are currently three first-line immunotherapy options used as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand 1 (PD-L1) expression (≥50%). This manuscript aims to evaluate the available data on atezolizumab (AT), cemiplimab (CE...

Descripción completa

Detalles Bibliográficos
Autores principales: Isla, Dolores, Sánchez, Alfredo, Casal, Joaquín, Cobo, Manuel, Majem, Margarita, Reguart, Noemi, Zugazagoitia, Jon, Bernabé, Reyes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420126/
https://www.ncbi.nlm.nih.gov/pubmed/37568465
http://dx.doi.org/10.3390/jcm12155063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420126/
https://www.ncbi.nlm.nih.gov/pubmed/37568465
http://dx.doi.org/10.3390/jcm12155063

Ejemplares similares